All In Biotech

Drug Trial Radar · NCT06205381

Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers

A Phase 1, Single And Multiple Ascending Dose, Food Effect, and Drug-Drug Interaction Study With Itraconazole, Midazolam and Fexofenadine Of Orally Administered AV078 In Healthy Adults

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

89

Actual

Start

Jan 31, 2024

Primary completion

Feb 8, 2025

Study completion Feb 8, 2025

Sponsor

Lead sponsor
Aeovian Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study in healthy adult volunteers is planned to evaluate the safety, tolerability, and pharmacokinetics (PK) of AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1). The study will begin with a standard exploration of safety and tolerability in sequential single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Subsequent cohorts will collect PK data to evaluate food effects and potential drug-drug interactions relevant to AV078.

Conditions

  • Healthy Participants

Interventions

  • AV078Drug

    Oral solution containing active ingredient, AV078

  • PlaceboDrug

    Oral solution with no active ingredients

  • ItraconazoleDrug

    Once daily oral dose of 200 mg itraconazole administered for 9 days

  • MidazolamDrug

    2.5 mg midazolam administered orally on day 1 and day 18

  • FexofenadineDrug

    120 mg fexofenadine administered orally on day 1 and day 18

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events (TEAEs).Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  2. Occurrence of clinically significant changes in physical examination (including neurological assessment).Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  3. Change in blood haematology values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  4. Change in blood biochemisty values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  5. Change in urinalysis values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  6. Change in lipid panel values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  7. Change in blood coagulation values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  8. Clinically significant ECG findings.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  9. Monitor for the emergence of suicidal ideation and behaviour using the Columbia-Suicide Severity Rating Scale (C-SSRS).Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
  10. Pharmacokinetics measured by area under the concentration-time curve in fasted and fed state.Time frame: Day 1 to Day 7 post-dose and final follow-up visit (Day 14)
  11. Pharmacokinetics measured by the maximum plasma concentration (Cmax) in fasted and fed state.Time frame: Day 1 to Day 7 post-dose and final follow-up visit (Day 14)
  12. Effects of itraconazole on the pharmacokinetics of AV078 measured by area under the concentration-time curve.Time frame: Day 1 to Day 15 post-dose and final follow-up visit (Day 23)
  13. Effects of itraconazole on the pharmacokinetics of AV078 measured by the maximum plasma concentration (Cmax).Time frame: Day 1 to Day 15 post-dose and final follow-up visit (Day 23)
  14. Effects of AV078 on the pharmacokinetics of midazolam and fexofenadine measured by area under the concentration-time curve.Time frame: Day 1, 2, 18 and 19 post-dose (midazolam) or Day 1-3, 18 and 19 post-dose (fexofenadine)
  15. Effects of AV078 on the pharmacokinetics of midazolam and fexofenadine measured by the maximum plasma concentration (Cmax).Time frame: Day 1, 2, 18 and 19 post-dose (midazolam) or Day 1-3, 18 and 19 post-dose (fexofenadine)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm

    Herston, Queensland, Australia

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.